Biocompatible nano-micro-particles by solvent evaporation from multiple emulsions technique
Source abstract
Abstract
In this study, a method based on a multiple emulsions system was developed for the production of polymeric nano and micro-vectors. The possibility to apply an unified preparation technique to different polymers, such as polyesters [polycaprolactone, poly-dl-lactide, poly(dl-lactide-co-caprolactone) = 70/30] and polyacrylates [poly(methylmethacrylate–acrylic acid) = 73/27], loaded with different model molecules (budesonide, tamoxifen, and α-tocopherol) was explored. After selecting the best operating conditions, especially for emulsification and separation, the technique proved to be readily adaptable for production of both nano and micro-particles with different morphologies, depending on type of polymer, and consequently on solvent used for solubilization: nano-particles, with a round shape and a smooth surface, for polyesters, otherwise micro-particles for the polyacrylate polymer, owing to the presence of hydrophilic co-solvents, that caused both an easy coalescence between the oil and water phases, thus enlarged particles size, and a high porosity. Even the yield of encapsulation was influenced by the presence of hydrophilic co-solvents, causing a higher yield for nano-vectors. Polyesters-based nano-vectors showed release times of molecules, linked to their degradation time, higher than 8 months that make them useful to formulate injectable or implantable drug delivery systems. Polyacrylate-based micro-vectors showed an enteric behavior, interesting for designing solid pharmaceutical formulations for oral delivery. Therefore, the technique demonstrated to assure a broad application in drug delivery research.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery · Innovative Microfluidic and Catalytic Techniques Innovation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Xiong XY, Guo L, Gong YC et al (2012) In vitro & in vivo targeting behaviors of biotinylated pluronic F127/poly(lactic acid) nanoparticles through biotin–avidin interaction. Eur J Pharm Sci 46:537–54410.1016/j.ejps.2012.04.011 ↗
2. Lee Y-S, Johnson PJ, Robbins PT, Bridson RH (2013) Production of nanoparticles-in-microparticles by a double emulsion method: a comprehensive study. Eur J Pharm Biopharm 83:168–17310.1016/j.ejpb.2012.10.016 ↗
3. Kılıçay E, Demirbilek M, Türk M, Güven E, Hazer B, Denkbas EB (2011) Preparation and characterization of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHX) based nanoparticles for targeted cancer therapy. Eur J Pharm Sci 44:310–32010.1016/j.ejps.2011.08.013 ↗
4. Bernardi A, Zilberstein A, Jäger E et al (2009) Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats. Br J Pharmacol 158:1104–111110.1111/j.1476-5381.2009.00244.x ↗
5. Kim B-S, Kim C-S, Lee K-M (2008) The intracellular uptake ability of chitosan-coated poly(d,l-lactide-co-glycolide) nanoparticles. Arch Pharmacal Res 31:1050–105410.1007/s12272-001-1267-5 ↗
6. Steichen SD, Caldorera-Moore M, Peppas NA (2013) A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci 48:416–42710.1016/j.ejps.2012.12.006 ↗
7. Torchilin VP (2007) Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 9:E128–E14710.1208/aapsj0902015 ↗
8. Spizzirri U, Iemma F, Altimari I, Curcio M, Puoci F, Picci N (2012) Grafted gelatin microspheres as potential pH-responsive devices. J Mater Sci 47:3648–3657. doi: 10.1007/s10853-011-6211-310.1007/s10853-011-6211-3 ↗
9. Béduneau A, Saulnier P, Benoit J-P (2007) Active targeting of brain tumors using nanocarriers. Biomaterials 28:4947–496710.1016/j.biomaterials.2007.06.011 ↗
10. Müller R, Jacobs C, Kayser O (2001) Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47:3–1910.1016/S0169-409X(00)00118-6 ↗
11. Carmen Varela M, Guzmán M, Molpeceres J, del Rosario Aberturas M, Rodriguez-Puyol D, Rodriguez-Puyol M (2001) Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. Eur J Pharm Sci 12:471–47810.1016/S0928-0987(00)00198-6 ↗
12. Couvreur P, Vauthier C (2006) Nanotechnology: intelligent design to treat complex disease. Pharm Res 23:1417–145010.1007/s11095-006-0284-8 ↗
13. Fattal E, Barratt G (2009) Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br J Pharmacol 157:179–19410.1111/j.1476-5381.2009.00148.x ↗
14. Barba AA, Dalmoro A, d’Amore M, Lamberti G (2013) In vitro dissolution of pH sensitive micro-particles for colon-specific drug delivery. Pharm Dev Technol 18:1399–140610.3109/10837450.2012.727005 ↗
15. Gaumet M, Vargas A, Gurny R, Delie F (2008) Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 69:1–910.1016/j.ejpb.2007.08.001 ↗
16. Medina C, Santos-Martinez M, Radomski A, Corrigan O, Radomski M (2007) Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 150:552–55810.1038/sj.bjp.0707130 ↗
17. Keck CM, Müller RH (2013) Nanotoxicological classification system (NCS)—a guide for the risk–benefit assessment of nanoparticulate drug delivery systems. Eur J Pharm Biopharm 84(3):445–44810.1016/j.ejpb.2013.01.001 ↗
18. Wang X, Wenk E, Hu X et al (2007) Silk coatings on PLGA and alginate microspheres for protein delivery. Biomaterials 28:4161–416910.1016/j.biomaterials.2007.05.036 ↗
19. Yang KK, Kong M, Wei YN et al (2013) Folate-modified—chitosan-coated liposomes for tumor-targeted drug delivery. J Mater Sci 48:1717–1728. doi: 10.1007/s10853-012-6930-010.1007/s10853-012-6930-0 ↗
20. ElBayoumi TA, Torchilin VP (2010) Current trends in liposome research. Methods Mol Biol 605:1–2710.1007/978-1-60327-360-2_1 ↗
21. Bayindir ZS, Yuksel N (2010) Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci 99:2049–206010.1002/jps.21944 ↗
22. Svenson S (2009) Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm 71:445–46210.1016/j.ejpb.2008.09.023 ↗
23. Letchford K, Burt H (2007) A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 65:259–26910.1016/j.ejpb.2006.11.009 ↗
24. Dalmoro A, Lamberti G, Titomanlio G, Barba AA, d’Amore M (2010) Enteric micro-particles for targeted oral drug delivery. AAPS PharmSciTech 11:1500–150710.1208/s12249-010-9528-3 ↗
25. Kabanov AV, Vinogradov SV (2009) Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew Chem Int Ed 48:5418–542910.1002/anie.200900441 ↗
26. Benita S (2006) Microencapsulation: methods and industrial applications. Taylor & Francis, New York
27. Freitas S, Merkle H, Gander B (2005) Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J Control Release 102:313–33210.1016/j.jconrel.2004.10.015 ↗
28. Pérez E, Benito M, Teijón C, Olmo R, Teijón JM, Blanco MD (2012) Tamoxifen-loaded nanoparticles based on a novel mixture of biodegradable polyesters: characterization and in vitro evaluation as sustained release systems. J Microencapsul 29:309–32210.3109/02652048.2011.651496 ↗
29. Kompella UB, Bandi N, Ayalasomayajula SP (2003) Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci 44:1192–120110.1167/iovs.02-0791 ↗
30. Krishnamachari Y, Madan P, Lin S (2007) Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int J Pharm 338:238–24710.1016/j.ijpharm.2007.02.015 ↗
31. Lopes R, Eleutério CV, Gonçalves LMD, Cruz MEM, Almeida AJ (2012) Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis. Eur J Pharm Sci 45:442–45010.1016/j.ejps.2011.09.017 ↗
32. Song XR, Cai Z, Zheng Y et al (2009) Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 37:300–30510.1016/j.ejps.2009.02.018 ↗
33. Sánchez A, Tobio M, González L, Fabra A, Alonso MJ (2003) Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. Eur J Pharm Sci 18:221–22910.1016/S0928-0987(03)00019-8 ↗
34. Bao T, Hiep N, Kim Y, Yang H, Lee B (2011) Fabrication and characterization of porous poly(lactic-co-glycolic acid) (PLGA) microspheres for use as a drug delivery system. J Mater Sci 46:2510–2517. doi: 10.1007/s10853-010-5101-410.1007/s10853-010-5101-4 ↗
35. Abismail B, Canselier JP, Wilhelm AM, Delmas H, Gourdon C (1999) Emulsification by ultrasound: drop size distribution and stability. Ultrason Sonochem 6:75–8310.1016/S1350-4177(98)00027-3 ↗
36. Gabor F (1999) Ketoprofen-poly(d,l-lactic-co-glycolic acid) microspheres: influence of manufacturing parameters and type of polymer on the release characteristics. J Microencapsul 16:1–1210.1080/026520499289266 ↗
37. Yang Y, Chung T, Ng NP (2001) Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 22:231–24110.1016/S0142-9612(00)00178-2 ↗
38. Sipos P et al (2005) Influence of preparation conditions on the properties of eudragit microspheres produced by a double emulsion method. Drug Dev Res 64:41–5410.1002/ddr.10425 ↗
39. Mainardes RM, Evangelista RC (2005) PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm 290:137–14410.1016/j.ijpharm.2004.11.027 ↗
40. Behrend O, Ax K, Schubert H (2000) Influence of continuous phase viscosity on emulsification by ultrasound. Ultrason Sonochem 7:77–8510.1016/S1350-4177(99)00029-2 ↗
41. Li MK, Fogler HS (1978) Acoustic emulsification. Part 1. Form the initial droplets. J Fluid Mech 88:499–51110.1017/S0022112078002232 ↗
42. Li MK, Fogler HS (1978) Acoustic emulsification. Part 2. Form the initial droplets. J Fluid Mech 88:513–52810.1017/S0022112078002244 ↗
43. Barba A, Dalmoro A, De Santis F, Lamberti G (2009) Synthesis and characterization of P(MMA–AA) copolymers for targeted oral drug delivery. Polym Bull 62:679–68810.1007/s00289-009-0040-4 ↗
44. Joshi DP, Lan-Chun-Fung YL, Pritchard JG (1979) Determination of poly(vinyl alcohol) via its complex with boric acid and iodine. Anal Chim Acta 104:153–16010.1016/S0003-2670(01)83825-3 ↗
45. Barba AA, Chirico S, Dalmoro A, Lamberti G (2009) Simultaneous measurement of theophylline and cellulose acetate phthalate in phosphate buffer by UV analysis. Can J Anal Sci Spectros 53:249–253
46. Coulson J, Richardson J (1991) Chemical engineering. Volume 2: particle technology and separation processes. Pergamon Press, Oxford
47. Ye WP, Du FS, Jin WH, Yang JY, Xu Y (1997) In vitro degradation of poly(caprolactone), poly(lactide) and their block copolymers: influence of composition, temperature and morphology. React Funct Polym 32:161–16810.1016/S1381-5148(96)00081-8 ↗
48. Grayson ACR, Cima MJ, Langer R (2005) Size and temperature effects on poly(lactic-co-glycolic acid) degradation and microreservoir device performance. Biomaterials 26:2137–214510.1016/j.biomaterials.2004.06.033 ↗
49. Gonçalves CMB, Tomé LC, Coutinho JAP, Marrucho IM (2011) Addition of α-tocopherol on poly(lactic acid): thermal, mechanical, and sorption properties. J Appl Polym Sci 119:2468–247510.1002/app.32952 ↗
50. Huang MH, Li S, Hutmacher DW, Coudane J, Vert M (2006) Degradation characteristics of poly(ϵ-caprolactone)-based copolymers and blends. J Appl Polym Sci 102:1681–168710.1002/app.24196 ↗
51. Ertl P (2008) Molecular drug properties. Wiley-VCH Verlag GmbH & Co, KGaA, Weinheim
52. Lee B, Richards FM (1971) The interpretation of protein structures: estimation of static accessibility. J Mol Biol 55:379–40010.1016/0022-2836(71)90324-X ↗